ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1999 entries already.
For its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFIT’s 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
Mereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
French Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing.
Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Dutch biotech Azafaros B.V. has closed a €25m Series A financing round.
Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline.
French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
The 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.